Compare · RCEL vs RMD
RCEL vs RMD
Side-by-side comparison of Avita Medical Inc. (RCEL) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RCEL and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.44B, about 221.0x RCEL ($128.6M).
- Over the past year, RCEL is down 31.8% and RMD is down 23.1% - RMD leads by 8.8 points.
- RCEL has been more active in the news (15 items in the past 4 weeks vs 6 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 7 for RCEL).
- Company
- Avita Medical Inc.
- ResMed Inc.
- Price
- $4.21+0.24%
- $193.21-1.43%
- Market cap
- $128.6M
- $28.44B
- 1M return
- +0.96%
- -6.57%
- 1Y return
- -31.82%
- -23.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 15
- 6
- Recent ratings
- 7
- 25
Avita Medical Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest RCEL
- SEC Form 424B5 filed by Avita Medical Inc.
- Avita Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Director Woody Joseph Fralin bought $40,949 worth of shares (10,000 units at $4.09), increasing direct ownership by 12% to 92,761 units (SEC Form 4)
- Director Mcnamara Robert was granted 22,214 shares, increasing direct ownership by 26% to 108,985 units (SEC Form 4)
- Director Woody Joseph Fralin was granted 62,761 shares, increasing direct ownership by 314% to 82,761 units (SEC Form 4)
- Director Tarnoff Michael E was granted 48,464 shares (SEC Form 4)
- Director Cook Jeremy Curnock was granted 22,214 shares, increasing direct ownership by 56% to 62,050 units (SEC Form 4)
- Director Crowe Suzanne was granted 22,214 shares, increasing direct ownership by 47% to 69,148 units (SEC Form 4)
- Director Reed Jan Stern was granted 22,214 shares, increasing direct ownership by 44% to 73,225 units (SEC Form 4)
- Director Woody Joseph Fralin bought $84,936 worth of shares (20,000 units at $4.25) (SEC Form 4)
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.